United States Gastric Cancer Diagnostic Procedure Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis by Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Types (Symptomatic and Asymptomatic), Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue, and Others), Procedures (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays, and Others), Offerings (Instruments, Reagents & Consumables, and Services), and Disease Indication (Early Gastric Cancer and Advanced Gastric Cancer)

No. of Pages: 158    |    Report Code: BMIRE00028016    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
United States Gastric Cancer Diagnostic Procedure Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. United States Gastric Cancer Diagnostic Procedure Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. United States Gastric Cancer Diagnostic Procedure Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increase in gastric cancer incidence
  • 5.1.2 Advancements in diagnostic technologies
  • 5.1.3 Rising demand for early cancer detection
5.2 Market Opportunities
  • 5.2.1 Rising focus on early detection and diagnostics for gastric cancer
  • 5.2.2 Growing availability of advanced diagnostic technologies
  • 5.2.3 Increasing adoption of non-invasive diagnostic procedures
5.3 Future Trends
  • 5.3.1 Increased use of non-invasive diagnostic technologies
  • 5.3.2 Advancements in biomarkers for gastric cancer detection
  • 5.3.3 Rising interest in personalized diagnostics for cancer treatment
5.4 Impact of Drivers and Restraints

6. United States Gastric Cancer Diagnostic Procedure Market Regional Analysis

6.1 United States Gastric Cancer Diagnostic Procedure Market Overview
6.2 United States Gastric Cancer Diagnostic Procedure Market Revenue 2020-2028 (US$ Million)
6.3 United States Gastric Cancer Diagnostic Procedure Market Forecast Analysis

7. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Healthcare Providers

7.1 Diagnostic Laboratories
  • 7.1.1 Overview
  • 7.1.2 Diagnostic Laboratories: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Hospitals
  • 7.2.1 Overview
  • 7.2.2 Hospitals: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cancer Research Institutes
  • 7.3.1 Overview
  • 7.3.2 Cancer Research Institutes: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Oncology Specialty Clinics
  • 7.4.1 Overview
  • 7.4.2 Oncology Specialty Clinics: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2031 (US$ Million)

8. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Symptom Types

8.1 Symptomatic and Asymptomatic
  • 8.1.1 Overview
  • 8.1.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)

9. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Body Fluid

9.1 Blood
  • 9.1.1 Overview
  • 9.1.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Urine
  • 9.2.1 Overview
  • 9.2.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Saliva
  • 9.3.1 Overview
  • 9.3.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Stomach Wash/Gastric Juice
  • 9.4.1 Overview
  • 9.4.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Tissue
  • 9.5.1 Overview
  • 9.5.2 Symptomatic and Asymptomatic: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)

10. United States Gastric Cancer Diagnostic Procedure Market – United States Analysis

10.1 United States
  • 10.1.1 United States Gastric Cancer Diagnostic Procedure Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 United States : United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 United States : United States Gastric Cancer Diagnostic Procedure Market Breakdown, by Healthcare Providers
    • 10.1.1.1.2 United States : United States Gastric Cancer Diagnostic Procedure Market Breakdown, by Symptom Types
    • 10.1.1.1.3 United States : United States Gastric Cancer Diagnostic Procedure Market Breakdown, by Body Fluid

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. United States Gastric Cancer Diagnostic Procedure Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Atlas-Link Biotech Co Ltd
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Bio-Rad Laboratories Inc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 MiRXES Pte Ltd
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Agilent Technologies Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 F. Hoffmann-La Roche Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 bioMerieux SA
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Thermo Fisher Scientific Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Illumina Inc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Vela Diagnostics Holding Pte Ltd
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Myraid Genetics Inc.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - U Market

  1. Atlas-Link Biotech Co Ltd
  2. Bio-Rad Laboratories Inc
  3. MiRXES Pte Ltd
  4. Agilent Technologies Inc
  5. F. Hoffmann-La Roche Ltd
  6. bioMerieux SA
  7. Thermo Fisher Scientific Inc
  8. Illumina Inc
  9. Vela Diagnostics Holding Pte Ltd
  10. Myraid Genetics Inc.
united-states-gastric-cancer-diagnostic-procedure-market